RISK FACTORS FOR MORTALITY AND TREATMENT OUTCOMES OF PATIENTS WITH CEFTRIAXONE RESISTANT E. COLI BACTEREMIA RECEIVING CARBAPENEM VERSUS BETA LACTAM/BETA LACTAMASE INHIBITOR THERAPY
Research Square (Research Square)